A recent study showed that the COPD assessment test was reliable and responsive for assessing health status in fibrotic ...

More than 200 patients have had their lung disease treatment reviewed following concerns their care at a Surrey hospital did not meet best practice guidance, a board report said. A review by the Royal ...

The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

2024 — Managing hard-to-treat respiratory illnesses like asthma and pulmonary fibrosis just got easier if a new drug-carrying molecule is as sneaky as its inventors ... COPD and BPD: Inhalation ...

Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

Idiopathic pulmonary fibrosis is a chronic, progressive, incurable lung disease, leading to irreversible lung tissue ...

Although Utahns do not smoke tobacco at the rate of Americans in most states, it doesn’t mean they are not vulnerable to lung ...

MannKind completes phase 1 trial of nintedanib DPI for pulmonary fibrotic diseases: Danbury, Connecticut Tuesday, November 5, 2024, 16:00 Hrs [IST] MannKind Corporation, a company ...